Listen to the article
In a significant legal development, four major pharmaceutical companies – AbbVie, AstraZeneca, Novartis, and Sanofi – must now defend themselves against claims of defrauding federal and state government healthcare programs, following a ruling by the U.S. Court of Appeals for the Ninth Circuit in Pasadena, California.
The court rejected the companies’ attempts to dismiss a whistleblower lawsuit brought under the False Claims Act (FCA) by Adventist Health System/West, a non-profit organization representing covered entities in California. The lawsuit alleges that the pharmaceutical giants overcharged hospitals and clinics participating in the Section 340B drug pricing program.
Established in 1992, the 340B program requires pharmaceutical manufacturers to sell outpatient medications at substantially discounted prices to eligible “covered entities” (CEs), primarily safety-net hospitals and clinics serving vulnerable populations. These healthcare facilities operate on thin margins while providing care to communities with high rates of poverty and uninsurance.
According to the lawsuit, the pharmaceutical companies knowingly charged prices exceeding the statutory ceiling – the maximum allowable price manufacturers can charge under the program. This ceiling is calculated as the average manufacturer price minus required rebates. The alleged overcharging occurred before 2019 amendments to the program that implemented substantial fines for pricing violations.
Adventist claims these pricing practices led to inflated reimbursements from Medicare and Medicaid, effectively defrauding these government healthcare programs of taxpayer funds.
The pharmaceutical companies had previously convinced a California district court to dismiss the complaint, arguing that Adventist lacked standing to bring the case. They contended that disputes over 340B payments should be handled through administrative procedures with federal and state governments rather than through litigation, and that Adventist was overstepping by attempting to enforce 340B compliance.
However, Adventist successfully appealed this decision, asserting that it had the right to pursue litigation under the False Claims Act to address fraud and recover losses on behalf of government programs. Adventist maintained it was not seeking to recover personal losses or directly enforce Section 340B.
In the appeals court opinion, Judge Roopali Desai wrote: “Because Adventist asserts legally cognizable claims for relief under the FCA and has satisfied the necessary pleading requirements, we reverse and remand for further proceedings.”
This ruling represents another chapter in the increasingly contentious landscape of pharmaceutical pricing litigation. The 340B program has become a particular flashpoint, with numerous legal challenges emerging in recent years. Several lawsuits have attempted to block a Department of Health and Human Services pilot scheme implementing a new rebate model that covered entities argue would cause significant harm and potentially force some facilities to close.
The pharmaceutical industry has long criticized aspects of the 340B program, claiming it has expanded beyond its original intent. Meanwhile, safety-net providers maintain the program is essential for their financial viability and ability to serve vulnerable populations.
In a separate but related development, Johnson & Johnson is presenting opening arguments today in the U.S. Court of Appeals for the Third Circuit in New Jersey, attempting to overturn what Bloomberg Law describes as the largest FCA judgment in history. The case involves a $1.6 billion penalty imposed by a district court in 2023 for alleged off-label promotion of two HIV/AIDS medications, Prezista and Intelence.
J&J’s appeal employs similar reasoning to the AbbVie-AstraZeneca-Novartis-Sanofi case, questioning whether former employees of its Janssen Products unit have constitutional standing to litigate on behalf of the government. The company is also contesting the size of the judgment, arguing it is excessive.
These cases highlight the ongoing tension between pharmaceutical pricing practices, government healthcare programs, and the legal mechanisms available to address alleged fraud and overcharging in America’s complex healthcare system.
Fact Checker
Verify the accuracy of this article using The Disinformation Commission analysis and real-time sources.
12 Comments
This lawsuit highlights the ongoing challenges around drug pricing and access, especially for healthcare providers serving disadvantaged communities. It will be interesting to see how the courts rule on the pharmaceutical companies’ culpability.
This is a significant ruling against pharmaceutical companies accused of overcharging hospitals and clinics participating in the 340B drug pricing program. It’s important to hold these companies accountable if they’ve been exploiting the system and overcharging vulnerable healthcare facilities.
Absolutely. The 340B program is meant to help clinics serving low-income populations access affordable medications. Any abuse of the system should be investigated and addressed.
This is an important case that could have major implications for the 340B program and drug pricing more broadly. Pharmaceutical companies need to be held accountable if they’ve been exploiting the system.
Agreed. Fairness and access to affordable medications are critical, especially for healthcare facilities serving disadvantaged communities.
Overcharging safety-net hospitals is a serious allegation. If proven true, it would undermine the intent of the 340B program to provide affordable medications to vulnerable populations. I hope this lawsuit leads to greater transparency and accountability.
It’s concerning to hear allegations of pharmaceutical companies overcharging safety-net hospitals and clinics. These facilities operate on tight budgets and need access to affordable medications to serve their communities.
I agree. Hopefully this lawsuit leads to more oversight and accountability around the 340B program to ensure it’s working as intended to support vulnerable populations.
The 340B program has always been a contentious issue, with drug companies pushing back against discounted pricing. This lawsuit seems to indicate that some companies may have crossed the line into fraudulent behavior.
You’re right, it’ll be crucial for the courts to carefully examine the evidence and determine if the pharmaceutical firms violated the terms of the 340B program.
I’m curious to see how the pharmaceutical companies respond to this lawsuit. It’s a complex issue, but patients and healthcare providers deserve fair pricing and transparency from these major drug companies.
You raise a good point. The outcome of this case could have broader implications for how the 340B program is administered and regulated going forward.